Jefferson Shreve sold Repligen Corporation (NASDAQ: RGEN)
Jefferson Shreve (R-IN), a U.S. Representative, has disclosed 1 trade in Repligen Corporation (RGEN) since 2025, a single sale, worth an estimated $33K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a sale: Jefferson Shreve sold $15,001 - $50,000 of Repligen Corporation (NASDAQ: RGEN) on April 7, 2025. Since that trade, RGEN is up +23.68% against the S&P 500 up +48.74%, an outperformance of -25.06%.
Data updated
Jefferson Shreve's RGEN trades vs the price
RGEN is up +23.68% since Jefferson Shreve sold on April 7, 2025, versus +48.74% for the S&P 500.
Performance since this trade
All Jefferson Shreve RGEN trades
Jefferson Shreve & RGEN trading FAQ
Is it legal for Jefferson Shreve to trade Repligen Corporation (RGEN) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Repligen Corporation (RGEN), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did Jefferson Shreve sell RGEN?
Jefferson Shreve disclosed a sale of $15,001 - $50,000 of Repligen Corporation (RGEN) on April 7, 2025, according to public STOCK Act filings.
How has RGEN performed since Jefferson Shreve's trade?
Since Jefferson Shreve sold RGEN on April 7, 2025, the stock is up +23.68%, versus +48.74% for the S&P 500 over the same period, an outperformance of -25.06%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional RGEN trades?
Quantellect tracks every disclosed congressional trade in Repligen Corporation (RGEN) on the Repligen Corporation congressional trading page, which aggregates filings across all members of Congress.
Jefferson Shreve's RGEN tradesAll congressional filings for Repligen CorporationJefferson Shreve's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.